Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.48 |
| ▸ | BRD4 | O60885 | 4/20 | 0.48 |
| ▸ | IGF1R | P08069 | 3/20 | 0.46 |
| ▸ | WEE1 | P30291 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 6/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30086522 | 1.00 | JAK2 (0.48) | JAK2BRD4IGF1RWEE1EGFR | |
| SCHEMBL23906607 | 0.91 | AXL (0.46) | JAK2BRD4IGF1RWEE1EGFR | |
| SCHEMBL30086484 | 0.91 | AXL (0.46) | JAK2BRD4IGF1RWEE1EGFR | |
| SCHEMBL30086287 | 0.89 | IGF1R (0.46) | JAK2BRD4IGF1RWEE1EGFR | |
| SCHEMBL23906843 | 0.89 | IGF1R (0.46) | JAK2BRD4IGF1RWEE1EGFR | |
| SCHEMBL23906723 | 0.87 | IGF1R (0.46) | JAK2BRD4IGF1REGFRJAK3 | |
| SCHEMBL30086424 | 0.87 | IGF1R (0.46) | JAK2BRD4IGF1REGFRJAK3 | |
| SCHEMBL23906621 | 0.85 | JAK2 (0.51) | JAK2BRD4IGF1REGFRJAK3 | |
| SCHEMBL30086282 | 0.85 | JAK2 (0.51) | JAK2BRD4IGF1REGFRJAK3 | |
| SCHEMBL23906666 | 0.84 | PLK4 (0.48) | JAK2BRD4IGF1RWEE1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2021203131-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | JAK2 1187/4885BRD4 3531/4885IGF1R 558/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | JAK2 1187/4885BRD4 3531/4885IGF1R 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.